Presentation

Calliditas Therapeutics is a specialty pharmaceutical company focused on developing medical products for patients with significant unmet medical needs in niche indications, where the company can partially or completely participate in the commercialization. Calliditas is focused on the development and commercialization of its lead product candidate Nefecon, which has successfully launched in the US (approved in Europe) for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is the first drug approved within this indication.

Recent highlights
First sale of Nefecon in the US market was reported on the 28th of January 2022. In Q1 2022 the drug has generated USD 1.9 million in revenues. Due to the monthly payment model, the company commented on seeing a continuous acceleration of sales when more patients are enrolled. In June 2022, the drug also received EMA’s approval.

Outlook
Since Nefecon is currently still the on drug on the market while competitors have not shown significant efficacies in eGFR (direct measurement of kidney function) like Calliditas. We expect the drug sales continue to accelerate and eventually reach blockbuster stage (>1billion in annual sales) in both the US and European markets. Besides, we also expect the company will continue to advance the developments of its second asset setanaxib.